The company processes copper scrap into various industrial products like bus bars, rods, and foils for customers in the automotive, power, and renewable energy sectors.
The company operates in a commodity-linked recycling business where margins are thin (1.3% net margin) and returns on capital (9.1% ROCE) are below the cost of capital, indicating a lack of durable competitive advantage despite claims of specialized IP.
Capital is primarily deployed into working capital and capacity expansion (35k to 45k MT), but the negative cash conversion and high debt-to-equity (1.0) suggest inefficient capital usage relative to the low margins generated.
The collapse was driven by a lethal combination of thin margins and a debt-heavy balance sheet. As interest rates remained elevated, the company's interest coverage—already a precarious 2.9—deteriorated further, while the negative cash conversion cycle forced a reliance on increasingly expensive short-term debt to fund inventory. The 1.3% net margin provided no cushion for commodity price volatility or the GST credit reversals that plagued the books. Eventually, the lack of pricing power and the burden of servicing debt for low-return capacity expansions led to a liquidity crunch, proving that revenue growth without cash flow is a vanity metric that ends in insolvency.
RichFakir rates Bhagyanagar India Ltd's business quality as poor — 40/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Bhagyanagar India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Bhagyanagar India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Bhagyanagar India Ltd's fair value is about ₹126 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →